INVESTOR RELATIONS

REASONS TO INVEST IN STEM CELL THERAPEUTICS

•Lead program addressing a major unmet need with a large commercial potential
- Stroke is the leading cause of serious, long-term disability 1
- On average, a stroke occurs every 40 seconds 1
- Only treatments available: tPA (<4% of ischemic patients treated) and aspirin
•Current lack of effective treatment for reducing and repairing damage caused by stroke
•Shortened path to regulatory approval, decreased development risk and cost due to current FDA approval status of the drugs used in NTx®-265
•Attractive therapeutic window of NTx®-265 (within 24-48hours post stroke) and easy administration method (avoid the need for invasive brain surgery)
•Encouraging results from BETAS Phase IIa stroke trial demonstrated positive drug related effects on visual, motor and cognitive recovery in patients who suffered acute ischemic stroke.
•Additional indications being explored, traumatic brain injury (TBI) and multiple sclerosis (MS); also representing major unmet needs and large commercial potential
•Clinical programs with strong partnering potential
•Issued and pending patents protecting SCT's extensive intellectual property portfolio
1 Source: NCHS and NHLBI. © 2001-06, American Heart Association
STOCK QUOTE
Symbol:
TSX:SSS
Last Trade: 0.275
Change: 0.00%
Volume: 87425
Date: 3/9/2010
Time: 3:59pm

Note: Quotes are delayed. For informational purposes only.

LETTER TO SHAREHOLDERS
+ 2008 Letter to Shareholders
FACT SHEET
©2004 - 2010 Stem Cell Therapeutics - All rights reserved